NetraMark will power Nurosene to collectively design the future of healthcare
TORONTO, Oct. 12, 2021 /CNW/ – Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on building a generation of better brains, is pleased to announce that it has signed a definitive agreement to complete the transaction (the "Transaction") to acquire all issued and outstanding shares of NetraMark Corp. ("NetraMark") as initially disclosed in a press release of the Company on August 10, 2021.
NetraMark, a pharmatech company, utilizes AI, novel mathematical methods, and quantum computing to optimize the path to new drug development, accelerate clinical trials and redefine the landscape of how disorders are treated. Founder Dr. Joseph Geraci, has spent the last five years developing proprietary algorithms that are being leveraged by various industries today. NetraMark's technology provides clear insight into patient populations that will lead the charge in research and development efficiency.
"The acquisition of NetraMark is pivotal for the long-term growth of Nurosene and being able to fulfill our vision. NetraMark's complex purpose-built AI and advanced computational functionality, coupled with our data insights, are critical to the disruption of the traditional healthcare model. NetraMark will advance the development of our Nuro app with innovative enhancements that will help us achieve our mission of building better brains," stated Ranj Bath, CEO of Nurosene.
Dr. Joseph Geraci, PhD, Founder and CEO of NetraMark added, "The vision of Co-Founder Daniel Gallucci, perfectly aligns with NetraMark's long term vision of ultimately redefining the future of healthcare. Together, I am confident that we will truly revolutionize and accelerate the path towards new and novel healthcare solutions."
The global artificial intelligence (AI) in healthcare market size is expected to reach USD 120.2 billion by 2028 and is expected to expand at a CAGR of 41.8% over the forecast period. AI technology has played a pivotal role in the ongoing COVID-19 pandemic and positively influenced related markets.1
"The size of the market and projected growth of AI in healthcare, leaves no question for Nurosene and the acquisition of NetraMark. The technology NetraMark has developed will position Nurosene to be a key player in this sector," said Ranj Bath.
As a result of the definitive agreement with NetraMark and the near-term closing, the management team and Board of Directors of Nurosene have made the decision to pivot its strategy away from its consumer facing supplement business to focus its resources entirely on accelerating the development of the Nuro app and drug development by implementing the advanced technology offerings of NetraMark's proprietary data analytics and intelligence. The shift in positioning represents the Company's decision to pursue AI and data-engineered mental health solutions based on predictive analytics to enhance the solutions provided by Nurosene's app and overall product portfolio.
NetraMark Corp., an AI and pharma-tech company, has developed proprietary solutions for pharmaceutical and biotechnology companies. These solutions allow clients to leverage small to large data in order to optimize clinical trials and drug development. This is accomplished by providing a superior understanding of their patient populations and these insights are also used to develop new drugs and nutraceuticals.
Founded in 2016 by Dr. Joseph Geraci, PhD, and Richard M. Brooks, LLB, NetraMark was built to address current gaps in the pharmaceutical market. Utilizing AI and machine learning, NetraMark provides powerful insights into how to treat patients at the individual level, instead of a 'one size fits all' model. NetraMark was built to accelerate the path towards new medications and nutraceuticals through leveraging the full extent of AI and machine learning.
Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI and machine learning. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.
For more information, visit www.nurosene.com.
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact. Specifically, this news release contains forward looking statements relating to, among others, activities of the Company's proposed acquisition of NetraMark, growth and other initiatives thereto.
Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
SOURCE Nurosene Health Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2021/12/c4863.html
(Bloomberg) — HSBC Holdings Plc has hired Jessica Lehmann as a managing director and head of U.S. debt capital markets syndicate amid a stretch of record issuance in the corporate bond market, according to people with knowledge of the matter.Most Read from BloombergHow France Turned the Humble Roundabout Into a Showcase for ArtWhat the Front Line of the U.S. Abortion Fight in Kentucky Looks Like NowNYC's Waldorf Gets Plush Renovation, Becomes Icon of China's OverreachThey Invented the Must-Have
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
'The Big Short' guy remains bearish. But he's long on this trio of stocks.
Shares of Chinese electric vehicle maker Nio (NYSE: NIO) have had positive momentum for more than a week now, and that has continued today. As of 11 a.m. EDT, Nio shares had gained 3%. Last week, Chinese electric vehicle and battery maker BYD, which is one of Warren Buffett's Berkshire Hathaway portfolio holdings, announced plans to collaborate with a fleet-as-a-service solutions joint venture to deploy up to 5,000 new EVs to fleet managers in the U.S. And yesterday, news came that global EV leader Tesla had produced a record volume of electric vehicles at its Shanghai factory in September, with the majority of those sales remaining in China.
Shares of AT&T Inc. dropped 0.6% in afternoon trading Wednesday, putting them on track to suffer the longest losing streak in a year, and as they headed for the lowest close since July 2010. The stock has shed 7.5% over the past six sessions, which would be the longest stretch of losses since the nine-day loss streak that ended Oct. 21, 2020. The selloff has boosted AT&T's implied dividend yield to 8.23%, making it the second-highest yielding stock in the S 500 , just below fellow communications
DatChat (NASDAQ: DATS), which develops a privacy-oriented messaging app, went public at $4.15 per share (and one warrant for an additional share) on Aug. 12. Let's see why DatChat has attracted so much attention. DatChat's Messenger and Private Social Network enable users to modify or delete the messages they've sent, hide encrypted messages, and set messages to be automatically deleted after a fixed time frame or a set number of views.
Growth stocks can be a thing of beauty. The trick, if you will, is to suss out growth stocks that won't rot on the vine, so to speak. While both of these biotech stocks have more than doubled in value in the past three years, I believe each of these healthcare equities still has a lot of room to run in 2022 and beyond.
Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.
Yahoo Finance's Brian Sozzi and Julie Hyman break down how Blackrock, Apple, and Qualcomm are faring in Wednesday's market.
Improved credit and minimal loan growth for these credit card players in Q3 could lead to reserve releases of capital.
Most of the index's highest-yielding stocks come with a big asterisk, but they're still worth a look.
Since 2014, Harvard-educated David Yermack, a professor of finance at New York University, has taught courses on cryptocurrency. “Crypto investors should be aware of the high volatility of these assets, the unregulated nature of the trading platforms and the numerous frictions and delays involved in executing trades,” says Yermack.
Shares of Globalstar (NYSEMKT: GSAT) were rising today on seemingly no company-specific news. Rather, it appears that investors may be pushing up Globalstar's shares after Apple announced that it will hold a product event next week. The satellite service tech stock jumped by as much as 15.8% this morning, but had gained a much tamer 3.1% as of 11:32 a.m. EDT.
Industry researchers dished out yet another warning that Micron's pricing power is under pressure.
A big trend in the stock market this year has involved so-called meme stocks. Select companies that Wall Street funds bet against as loser stocks saw their shares quickly skyrocket in price thanks to individual investors buying in after teaming up through social media sites like Reddit to hurt the short-sellers. One stock that got a lot of attention for getting sucked up into this craze was AMC Entertainment Holdings (NYSE: AMC).
There are a lot of…interesting stocks on Robinhood's Top 100 list. From Nikola Motors (NASDAQ: NKLA), which is a known fraud with zero revenue and a $4.2 billion market cap, to multiple companies that added "blockchain" to their name to ride the recent excitement in cryptocurrencies, there are a lot of high-risk investments people are making on Robinhood right now. Roblox (NYSE: RBLX), Alphabet (NASDAQ: GOOG)(NASDAQ: GOOGL), and Taiwan Semiconductor (TSMC) (NYSE: TSM) are three Robinhood stocks that are great long-term picks.
(Bloomberg) — Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.Most Read from BloombergHow France Turned the Humble Roundabout Into a Showcase for ArtWhat the Front Line of the U.S. Abortion Fight in Kentucky Looks Like NowWhat Comes After GE’s 129 Years of Greenhouse GasThey Invented the Must-Have Instrument for the
West Texas Oil price just crossed US$80 for the first time in 7 years. Naturally, this re-ignited the interest in oil stocks that show the world they are not just dead yet, despite the climate activists shoveling dirt in their faces. Although the oil price is back to the highs, some oil companies like Chevron Corporation (NYSE: CVX) might be undervalued. This article will examine that valuation from the discounted cash flow (DCF) perspective.
George Soros has come around on crypto. Maybe you should, too?
Gerard Cassidy, RBC Capital Markets Head of U.S. Bank Equity Strategy and Large Cap Bank Analyst, reacts to JPMorgan's Q3 earnings beat and gives outlook for the banking sector.
NetraMark will power Nurosene to collectively design the future of healthcare